Search Results

Featured Topics

Toggle

Showing 23 of 23 results

COPAXONE Label Now Indicates Its Use in Breastfeeding Mothers with Relapsing Multiple Sclerosis

New Safety Data on treatment with COPAXONE glatiramer acetate of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis

Teva Announces Approval of Three Times A Week COPAXONE 40 mg mL in Russia for the Treatment of Relapsing Remitting Multiple Sclerosis

Let s talk about Multiple Sclerosis MS

  1. Patients and Caregivers
  2. Life Effects

Teva Presents 25 year Safety Data from Longest Continuous Trial of COPAXONE glatiramer acetate injection for the Treatment of Relapsing Forms of Multiple Sclerosis

Teva Reinforces Focus on Advancing Multiple Sclerosis Treatment at 31st ECTRIMS Congress

Kat Naish

  1. Patients and Caregivers
  2. Patient Contributors
Kat has lived with MS and its mental health related ups and downs for over half a decade She loves to write and is passionate about photography

Teva to Highlight New Data in Multiple Sclerosis at Joint ECTRIMS ACTRIMS Congress in Paris

Teva to Present Latest Data in Multiple Sclerosis at 2016 ECTRIMS Congress in London

Birgit Bauer

  1. Patients and Caregivers
  2. Patient Contributors

Willeke Van Eeckhoutte

  1. Patients and Caregivers
  2. Patient Contributors
Willeke Van Eeckhoutte is a writer and a voluntary disability awareness advocate living with cardiovascular disease CVD and multiple sclerosis MS

New Safety Data on treatment with COPAXONE glatiramer acetate of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis COBRA study presented at the 7th Congress of the European Academy of Neurology EAN

More Children vs My Health Why MS Changed My Mind about Expanding My Family

  1. Patients and Caregivers
  2. Life Effects
Kat Naish explores why she changed her mind about having a second child after her multiple sclerosis MS diagnosis

Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials

Teva and Active Biotech to Continue with the Development of Nerventra Laquinimod for Multiple Sclerosis Following Confirmation of CHMP Opinion

New Survey Highlights Misconceptions about Family Planning among Women with Relapsing Forms of Multiple Sclerosis RMS

National Survey Reveals Majority of Women Newly Diagnosed with Multiple Sclerosis Have Concerns They Aren t Discussing with Their Healthcare Team

What are Biologics and Biosimilars

  1. Home
  2. News and Media
  3. Feature Stories
We explain the difference between biologics and biosimilars and showcase Teva s innovative work in this space

Teva to Present Multiple Sclerosis Data at 67th American Academy of Neurology AAN Annual Meeting in Washington D C

Robert Joyce

  1. Patients and Caregivers
  2. Patient Contributors

Teva and Active Biotech Remain Committed to the Development of NERVENTRA laquinimod for Multiple Sclerosis Following the Negative Opinion from the EMA s CHMP

Data to be Presented at MS Boston 2014 Joint ACTRIMS ECTRIMS Meeting Underscore Teva s Commitment to Developing Solutions to Meet the Needs of the Multiple Sclerosis Community

Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington s Disease Trial